Skip to main content
. 2024 Jun 11;27(3):201–214. doi: 10.4048/jbc.2024.0065

Table 7. Summary of the published studies that used clinicopathologic parameters to predict Oncotype DX recurrence score in Korea and comparison to our current study.

Variable Lee et al., 2019 [3] Yoo et al., 2020 [4] Kim et al., 2023 [5] Current study
Patients
Training group 340 191 175 300
Validation group 145 264 122 117
Clinicopathological parameters included in predictive model Nuclear grade (1, 2 or 3), ER (Allred score), PR (Allred score), LVI (present or absent), Ki-67 (%) Nuclear grade (1–2 or 3), PR (negative or positive), Ki-67 (%) Nuclear grade (1–2 or 3), PR (negative or positive), Ki-67 (%) Age (≤ 50 or > 50), histologic type (IDCa or others), histologic grade (1 or 2–3), necrosis, PR (negative or positive), Ki-67 (≤ 20% or > 20%)
ODX RS cutoff values ≤ 25 (LR), > 25 (HR) ≤ 25 (LR), > 25 (HR) ≤ 25 (LR), > 25 (HR) Age ≤ 50:≤ 20, Age > 50:≤ 25 (LR)
Age ≤ 50: > 20, Age > 50:> 25 (HR)
(regardless of age) (regardless of age) (regardless of age)
Ki-67 scoring method No detailed explanation, Ki-67 LI (0–100) No detailed explanation, Ki-67 LI (0–100): Ki-67 LI (0–100): Systematic evaluation of Ki-67 scoring methods:
Percentage of positive cells by IHC IKWG scoring method using an automated image analysis program used for pathology reports at their institution 1) Average vs hotspot vs hottest spot using QuPath
2) Roche-analyzed Ki-67 scores according to IKWG recommendations
Type of prediction model Nomogram Nomogram Automatic calculator based on equation Simplified score: At least three of the six items are applicable from routine pathology report
Computational process required Computational process required Computational process required No computational process required

PR = progesterone receptor; ER = estrogen receptor; IDCa = invasive ductal carcinoma; LVI = lymphovascular invasion; ODX RS = Oncotype DX recurrence score; LR = low risk; HR = high risk; Ki-67 LI = Ki-67 labeling index; IHC = immunohistochemistry; IKWG = International Ki-67 in Breast Cancer Working Group.